Damora Therapeutics (DMRA) saw its stock price soar 7.88% during intraday trading on Monday, following a significant announcement regarding its executive leadership and board composition.

The biotechnology company announced the appointment of Jennifer Jarrett as its new President and Chief Executive Officer, effective March 30, 2026. Jarrett brings nearly three decades of executive experience in biotech, technology, and finance, most recently serving as Chief Operating Officer of Arcus Biosciences. Her background includes leadership roles at Uber Technologies, serving as CFO of Medivation, and two decades in investment banking, positioning her to guide Damora's strategic development.

Concurrently, Damora strengthened its Board of Directors by adding Cameron Turtle, CEO of Spyre Therapeutics, and Mike Landsittel, former CFO of Blueprint Medicines. Peter Harwin was named Chairman of the Board. Investors reacted positively to this leadership refresh, viewing the infusion of seasoned biotech executives as a catalyst to accelerate the development of Damora's lead program, DMR-001, and advance its pipeline of therapies for blood disorders.